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As part of long term commitment of the Biologicals and Vaccines Committee (B&V) of the International
Federation of Pharmaceutical Manufacturers and Association (IFPMA) to provide expert input to the
WHO on their recently ﬁnalized GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS
(SBPs), and in response to WHO’s request, the IFPMA B&V prepared a clinical case study at a recent WHO
workshop in Seoul, Korea. The case study, presented by Mark Fletcher on behalf of B&V, involved a model
scenario for a clinical efﬁcacy trial to support the approval of a Similar Biotherapeutic Product (SBP) as
part of the required comparative clinical program against a Reference Biotherapeutic Product (RBP). A
key goal was to understand and illustrate key clinical and statistical principles, and considerations
described in the WHO Guidance for regulatory authorities when designing and implementing WHO
guidelines and post-approval regulatory oversight for SBPs.
Using this model SBP/RBP pair, an interactive discussion was carried out among the workshop
participants on the pros and cons of using equivalence vs. non-inferiority designs to assess the two
products’ similarity. Through discussion of the case, the complexity of demonstrating similar efﬁcacy and
safety of a SBP vs. RBP for biotherapeutic products is outlined and discussed in the context of the key
principles laid out in the recently published WHO GUIDELINES ON EVALUATION OF SIMILAR BIO-
THERAPEUTIC PRODUCTS (SBPs). The exercise illustrates the need for a case-by-case approach when
interpreting clinical data from SBP dossiers to adequately assure similar efﬁcacy and safety of SBPs for
any studied indication.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
A biosimilar [aka, similar biological medicinal product, similar
biotherapeutic product (SBP)], is a new biological medicinal product
claimed to be “similar” to an already approved “reference product”
[aka Reference Biotherapeutic Product (RBP)]. A SBP is intended to
be marketed by an independent pharmaceutical manufacturer,
subject to all applicable data protection periods and/or intellectual
property rights regarding the originator product. Comparative
quality, non-clinical and clinical studies are needed to substantiateA, Chemin Louis-Dunant15,
International Federation of
A).
ll rights reserved. The World Healththe similarity of structure/composition, quality, safety and efﬁcacy
between the new SBP and the chosen approved andwell established
RBP. The same RBP should be used throughout the entire assess-
ment in order to generate valid data and conclusions. Furthermore,
the active substance of a SBPmust be similar, in both molecular and
biological terms, to the active substance of the RBP, as should the
pharmaceutical form, strength and route of administration.
The IFPMA B&V has welcomed the request fromWHO to provide
support and expert comments for their stated need to develop
a global regulatory guideline for biosimilar products, coming out of
the Informal Consultation on Regulatory Evaluation of Therapeutic
Biological Medicinal Products, held 19e20 April, 2007, WHO HQ,
Geneva. Throughout the process of drafting, revising and ﬁnalizing
the WHO Guidelines document over the ensuing two and a half
years, the IFPMA B&V has continued to work very closely and dili-
gently with the WHO to provide guidance [1], comment and clarityOrganization has granted the Publisher permission for the reproduction of this article.
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evidence-based approach that is needed in assessing SBP dossiers.
The IFPMA B&V’s input has focused on key points regarding the
characteristics of an SBP that must be assured in order to provide
patients with highly similar, clinically indistinguishable, safe
treatment and predictable efﬁcacy, when compared to the well
established RBP against which it is tested. These points include
a range of quality, non-clinical and clinical scientiﬁc standards as
well as post-marketing surveillance/risk management, inter-
changeability, substitution, nomenclature and labeling issues that
must be addressed.
The IFPMA B&V has also emphasized that the purpose of the
SBP’s clinical development program is to obtain approval of the SPB
for one or more of the indications for which the RBP is already
approved. When the physio-chemical structure of the SBP is shown
to be highly similar to the RBP, while the SBP could, in principle, be
approved to obtain approval of all the RBP’s indications, all indi-
cations must be justiﬁed, and in many cases will require additional
clinical data for each indication sought. This is especially true in
other patient groups where the pathophysiology, background,
demographics, co-morbidities and/or optimal dose may be
different.
Once the WHO Guidelines document was ﬁnalized, the IFPMA
B&Vwas asked byWHO to continue providing experts’ inputs in the
implementation of those Guidelines through a series of workshops
for regulators and interested parties. To this end, the WHO
requested that the IFPMA B&V prepare and lead a case study to
illustrate issues around comparisons of equivalence and non-
inferiority study designs as part of their Implementation Work-
shop in Seoul Korea in August 2010.
This article summarizes that clinical case study of a hypothet-
ical Similar Biotherapeutic Product (SBP) with the purpose of
highlighting some of the key points and issues facing a clinical
program that is intended to support its regulatory approval. It
illustrates some of the concepts and principles laid out in the WHO
guidance in the context of how to design and interpret pivotal
studies and the subsequent data that is generated as part of the
required comparative clinical program against a well established
innovator product (Product X, the RBP). More speciﬁcally, this
exercise outlines and discusses clinical and statistical consider-
ations when designing conﬁrmatory clinical efﬁcacy trials to
ensure a successful SBP program. This includes the importance of
a thorough understanding of the robustness and effect size of the
available RBP’s clinical efﬁcacy data, and the clinical endpoints
used to demonstrate that efﬁcacy. However, designing, executing
and interpreting data from a pivotal trial(s) assumes that prior
extensive characterization and comparison of any proposed SBP
has been carried out against a deﬁned RBP (including a compre-
hensive Chemistry and Manufacturing Control (CMC), preclinical
safety and pharmacology program, as summarized above), and
that such data has demonstrated the SBP to be highly similar to
that RBP.
Using this model SBP/RBP pair, a series of questions and
discussion of possible responses provides an opportunity for
illustrating key clinical and statistical principles and considerations
described in the WHO Guidance for regulatory authorities when
designing, implementing, and utilizing guidelines and post-
approval regulatory oversight for approval of SBPs.
Interpreting clinical data from SBP dossiers to adequately assure
similar efﬁcacy and safety of SBPs for any studied indications is
a key goal for regulatory authorities being presented dossiers from
SBP drug development sponsors. Through discussion of this case,
a more speciﬁc goal of the exercise is to illustrate the complexity of
demonstrating similar efﬁcacy and safety of a SBP vs. a chosen RBP
for large complex biotherapeutic products, and the need for a case-by-case approach, though within the framework of principles laid
out by the WHO guidance [2].
2. Case study
2.1. General considerations and goals of the case study
2.1.1. Limitations/disclaimer
The model product described and discussed in this exercise is
not real. The product descriptions and data results, while designed
to be realistic in character and effect size, do not relate to any
speciﬁc approved product or product in development. Therefore
the outcomes and data described in this case study in no way
represent a true outcome of a program or any speciﬁc product, but
rather a composite of a number of possible drug products. Its
purpose is to provide sufﬁcient qualitative and quantitative infor-
mation to be realistic. However, the data and discussion of issues
that such data brings forward has been designed as a tool to
highlight a range of important clinical implications in choosing
study designs and assessing the subsequent clinical data.
2.1.2. Assumptions/key principles regarding availability of
chemistry, manufacturing, and controls (CMC), preclinical/early and
clinical data
A prerequisite for the initiation of conﬁrmatory clinical trials
such as the ones discussed in this exercise must include the avail-
ability of robust, comprehensive physicochemical and biological
characterization data (including, CMC, PK/PD proﬁles) of the SBP in
head-to-head comparisons with the selected RBP that support
a high degree of similarity between the SBP being developed and
RBP. For the purpose of this teaching exercise, an assumption is
made that the above requirements have already been met and that
the next steps are focused on designing the pivotal efﬁcacy trial(s)
which will support the highly similar efﬁcacy and safety of the new
SBP by comparing its clinical performance in a blinded, randomized
and controlled clinical trial that is well-designed and able to
demonstrate that the SBP is clinically comparable to the reference
product for which it is being developed, the RBP.
Key components of designing and interpreting the results of
such a pivotal comparative clinical trial include:
 A clear understanding of the RBP product proﬁle in treating the
target subject population;
 Choosing the best clinical model(s), primary efﬁcacy
endpoint(s)and comparability margin based on that efﬁcacy
endpoint;
 Choosing the trial objective to be utilized to show similarity for
the two biotherapeutic products (i.e. equivalence or non-
inferiority) and
 Calculating the appropriate sample size based on these
parameters;
 Interpreting the data.
The following sections discuss each of these trial components
and key issues that need to be addressed when considering them.
2.2. Proﬁle of Product X (the RBP)
The reference biotherapeutic product (Product X) which forms
the basis for the comparative analysis to be discussed in this
exercise is summarized in Table 1.
The efﬁcacy of Product X (which will subsequently be
referred to as the RBP) has been demonstrated clinically through
the use of a number of primary outcome parameters, the twomost
common being well established composite efﬁcacy endpoints
Table 1
Product X’s Key Clinical Attributes.
Product X is a parenterally administered innovator biotherapeutic antagonist of a key pathologic mediator that is involved in a number of chronic clinical diseases.
Product X has been approved in US, EU and many global markets for multiple indications, each of which has been based on a full licensing dossier.
Patient populations approved for treatment with Product X have a range of varied demographics and co-morbidities, and dosing/side effect proﬁles are somewhat
different across some of the indications.
Efﬁcacy in each of the approved indications [Target Populations (TPs)] has been studied, and Product X approved for the respective indications, based on a number of
clinically validated, regulator-accepted and population-speciﬁc endpoint measures.
Safety issues are well described and include serious adverse events that are dose/exposure and patient population related, and accepted as part of the agent’s
risk-beneﬁt ratio.
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treatment.2.3. Choosing the clinical model, efﬁcacy endpoint, trial design and
sample size for conﬁrmatory clinical trial
Conﬁrmatory evidence to demonstrate similar efﬁcacy of the
SBP and the chosen RBP will usually have to be demonstrated in
adequately powered, randomized, and controlled clinical trial(s).
The key endpoint measured and dosage used for a particular indi-
cation for which the approval is sought should represent a clinical
test system that is known to be sensitive enough to detect potential
differences between the SBP and the RBP. In this exercise hypo-
thetical parameters Y and Z are identiﬁed as outcome parameters
that have been previously well accepted measures of whether
a given study subject is a treatment responder to the RBP. While
similar, the target population’s responses to efﬁcacy parameters Y
and Z are slightly different in their magnitude and time course.
Fig. 1 illustrates the pharmacodynamic responses of subjects to the
RBP as measured by parameters Y and Z.
The RBP responder rate data in Fig. 1 demonstrate that
improvement in parameter Y peaks by w12 weeks after start of
treatment, regardless of dose (upper panel), while improvementsFig. 1. Comparison of the time course and dose response of target patients (0.25e1.0 of
full dose) to Product X (the RBP) using efﬁcacy parameter Y (upper panel) and Z (lower
panel). *Tmax ¼ Time to maximum effect. Blue vertical line ¼ Possible efﬁcacy
endpoint.in Parameter Z continue for up to w26 weeks, again regardless of
the dose (lower panel).
Choosing which of the two parameters would be better for
detecting differences between the SBP and RBP if they existed
depends on the time point selected for assessment.
At the workshop in Korea, the workshop participants were
asked “What are the pros and cons of using efﬁcacy parameter Y vs. Z
at 12 weeks as the primary endpoint for assessing similar efﬁcacy of
the SBP vs. the RBP in the target population?” and to “Discuss the
advantages and limitations of a 12 week vs. 26 week (6 month) study
design, when considering that RBP treatment of the Target Population
has generally required trials of 26 weeks duration or longer for the
original approval”. The key patient population for which the RBP
had been approved was a chronic illness, and the RBP’s approval
was based on efﬁcacy endpoints at 26 weeks or longer. Comparing
the two possible parameters to assess efﬁcacy and knowing that the
chosen parameter should be sensitive enough to detect potentially
important clinical differences between the SBP and the RBP, the
choice of parameter Z seemed to be the best in this circumstance,
since the 26 week endpoint still appeared on a linear part of the
efﬁcacy dose response curve. For this reason, a 26 week endpoint
was felt to be most appropriate for assessing the similarity of the
SBP to this RBP.2.4. General principles regarding: clinical efﬁcacy trial designs
2.4.1. Choice of equivalence (EQ) vs. non-inferiority (NI)
Once the endpoint has been selected for comparison of the SBP
and RBP in a pivotal efﬁcacy trial, a decision is needed as towhether
an EQ or NI design is most appropriate. The choice of an EQ vs. a NI
design has implications for both the sample size needed, as well as
the interpretation of the resulting data (which needs to be pre-
speciﬁed in the statistical plan). The WHO guidance states that
“In principle, equivalence designs (requiring lower and upper
comparability margins) are clearly preferred for the comparison of
efﬁcacy and safety of the SBP with the RBP”, but that “Non-inferi-
ority designs (requiring only one margin) may be considered if
appropriately justiﬁed” [2].
The EQ design is preferred because it most closely follows the
intended spirit of the comparative assessment. In essence, equiv-
alent efﬁcacy of two medicinal products means they have similar
(no better and no worse) efﬁcacy, and any observed differences are
of no clinical relevance.
The equivalence approach tests for both possibilities. The NI
approach does not and only requires that the SBP be no worse than
the RBP without looking if it might actually be better than the RBP.
The WHO states that “While both of the designs can be used, their
advantages and disadvantages should be well understood.”
One of the key goals of this case study (and the discussion that
follows in this section) is to outline some of the issues in choosing
an EQ vs. NI design in conducting pivotal efﬁcacy trials and what
the advantages and limitations of each approach might be when
interpreting the subsequent clinical data. However, it should be
Fig. 2. Derivation of Comparability Limits: Estimate Effect Size of Efﬁcacy Parameter(s)
Y and Z. Vertical axis is % of subjects responding. For each parameter the estimate of
effect size is the % of subject responding to the RBP minus that to the placebo.
Table 2
Example of summary data comparing efﬁcacy rates of the RBP using parameters Y
and Z.
Parameter Y Response Rates In the
Target Population at 12 weeks
Mean%, [range]
Parameter Z Response Rates In the
Target Population at week 12
Mean%, [range]
Placebo Rate RBP Rate Placebo Rate RBP Rate
25 [11e42] 60 [46e74] 9 [3e20] 37 [22e55]
Parameter Y Effect Size:
Mean, [95% CI]
35, [28, 43]
Parameter Z Effect Size
Mean, [95% CI]
28, [21, 35]
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demonstration of similarity of a SBP to its RBP in a pivotal study is
generally necessary, but may not always be sufﬁcient by itself to
exclude clinically signiﬁcant differences between the SBP and RBP.
For example, the SBP and RBP might be shown to be similar on
efﬁcacy, but new safety or immunogenicity ﬁndings may indicate
that the SBP is different from the RBP in a clinically meaningful way.
In developing the study design, the concepts of comparability
limits, which require a strong understanding of the effect size
demonstrated by the reference biotherapeutic product (RBP) and
the robustness of the data that support it, are very important and
discussed brieﬂy below.
2.4.2. Comparability margins/limits: what are they?
Selection of the primary efﬁcacy endpoint and statistical design
of the pivotal clinical study as well as calculating the appropriate
samples sizes to assure adequate power is a multi-step process that
requires a clear understanding of comparability margins (some-
times called comparability limits, or just the “margin”) for the
particular efﬁcacy endpoint to be assessed. As outlined in the WHO
Guidance, “the selected margin should represent the largest
difference in efﬁcacy that would not matter in clinical practice” [2].
Saying it another way, “Treatment differences within this margin
would thus, by deﬁnition, be acceptable because they have no
clinical relevance” [2].
By their nature, comparability margins for any given efﬁcacy
endpoint are a clinical judgment and often are not well established
or universally agreed upon, so choice of margin size must be well
justiﬁed by Sponsors, usually based on a combination of expert
opinion and published analyses and should be discussed and
agreed to by regulators prior to study initiation.
2.4.3. Derivation of the comparability margin
2.4.3.1. Review of literature. The ﬁrst step in agreeing upon such
a margin is an understanding of what is the expected effect size for
treating the target population with the RBP and how robust is this
effect, i.e. how reliably has the RBP demonstrated this magnitude of
beneﬁt (usually over a placebo) when compared over multiple
independent clinical trials (usually data generated in support of the
original approval dossier of the RBP). Such an understanding
usually requires a comprehensive review of available literature/data
on the efﬁcacy endpoint parameter(s) of interest. Regulators must
assure themselves that Sponsors provide justiﬁcation of the
robustness of the efﬁcacy endpoint(s) to be used in the pivotal
efﬁcacy trial(s). Justiﬁcation usually requires:
 A thorough review of available data on the RBPs efﬁcacy
response in the target patient population as measured by the
chosen efﬁcacy parameter(s);
 Pharmacokinetic/pharmacodynamic dose response informa-
tion: e.g. time to Emax (maximum effect) over a range of safe
doses;
 Data on the effect size (magnitude of the efﬁcacy response vs.
placebo or other active therapy);
 Safety information and effects of dose/exposure;
 Data on the RBP’s immunogenicity-rate, character, and clinical
impact of any anti-drug responses;
 Available data on the chosen efﬁcacy parameter’s response to
other agents with similar mechanism of action as the RBP.
Fig. 2 lays out schematically how the effect size is estimated for
the two related hypothetical efﬁcacy parameters Y and Z, in a given
trial, while Table 2 and Fig. 3 extend this information to illustrate
what summary data on the effect size of Y and Z from available
literature might look like, and how the estimated effect size is usedto derive an acceptable comparabilitymargin and sample sizes for an
Equivalence (EQ) or a Non-inferiority (NI) trial design, respectively.
For a given efﬁcacy parameter, the effect size is deﬁned as the
measured effect seen with active treatment (e.g. RBP) minus the
effect with placebo treatment. Fig. 2 indicates that the effect size for
parameter Y is approximately 60e25 ¼ 35%, while that of param-
eter Z is approximately 38e9 ¼ 28%.
Table 2 demonstrates and compares hypothetical data on the
means and 95% conﬁdence intervals (CIs) of the effect size (i.e. the
difference between the RBP and the control group [placebo]) for the
response parameters Y and Z. The data would be a summary based
on review of many studies utilizing these endpoints in clinical trials
of RBP in the target patient population.
2.4.3.2. Select response parameter and comparability margin/limit.-
Based on the information in Fig. 1 above, parameter Z is chosen by
the hypothetical sponsor of the SBP as the efﬁcacy endpoint to use
in the pivotal trial and its effect size and variability (summarized in
Table 2) is then utilized to derive the comparability margin and
sample sizes required for an EQ vs. NI trial design (summarized
schematically in Fig. 3).
In this exercise, the Sponsors have selected parameter Z for the
primary efﬁcacy endpoint of their pivotal trial and therefore the
effect size to carry forward in deriving the comparability margin is
28%. Fig. 3 demonstrates that based on parameter Z’s effect size of
28%, when patients are treated with the RBP a clinical judgment
needs to be made as to what fraction of this expected effect size can
treatment with the SBP differ from treatment seen with the RBP
and still be considered clinically similar? For purposes of this
exercise, a 25% relative difference in effect size was chosen as the
maximum difference between the SBP and RBP’s response rates
such that clinical experts would still feel comfortable saying the
SBP’s clinical efﬁcacy was not substantially different from that of
the established product, the RBP. Based on this relative fraction, the
absolute comparability margin in this exercise would be
0.25  28% ¼ 7%. In practical terms, and stated as an over-
simpliﬁcation, if a randomized, blinded, RBP-controlled clinical trial
Fig. 3. Selection of comparability margin/limits.
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with the SBP vs. the RBP, and the upper limit of the 95% conﬁdence
interval for the absolute difference in response rates between the
SBP and RBP is less than 7%, the SBP’s efﬁcacy would be considered
to be within the comparability margin (i.e. the two products would
be considered clinically similar).
While the approach of using the point estimate of the effect size
as a starting point for estimation of the comparability margin is
reasonable (in our example, it was 28% e see Table 2), at least one
regulatory authority has suggested themore conservative approach
of basing the effect size on the lower limit of the conﬁdence
interval, (in our example, 21%), which would have lead to a margin
of 0.25  21% or approximately 5% (see CHMP and FDA draft
guidance documents [3,4]).2.5. Comparison of sample size estimates for EQ vs. NI designs
Once the efﬁcacy parameter Z is chosen, the effect size charac-
terized and the comparability margin determined, this information
can be used to calculate sample sizes for the clinical trial. Table 3
below provides an example of samples sizes for an EQ vs. NI
design approach and compares such sizes based on a comparability
margin of 7% vs. 4.2% and power of 90% or 80%. Key points toTable 3
Comparison of sample size estimates for EQ vs. NI designs using efﬁcacy parameter Z
(Parameter Z Effect Size ¼ 28%).
Equivalence Trial Design Non-Inferiority Trial
Design
Assumptions: 2-Sided
Alpha ¼ 5%, Param Z
(RBP) ¼ Param Z
(SBP) ¼ 37%
Assumptions: 1-Sided
Alpha ¼ 2.5%, Param Z
(RBP) ¼ Param Z
(SBP) ¼ 37%
Comparability Margin (%) # per Treatment Group # per Treatment Group
90% Power 80% Power 90% Power 80% Power
7.0 1000 747 815 589
4.2 2777 2075 2264 1634
The bold values in the comparability margin section indicate the choice of the 7.0%
margin as the choice carried forward into the following ﬁgures and discussion.consider are that as the comparability margin gets smaller, the
sample sizes rapidly increase, and when using the same endpoint
and comparability margin, an EQ design will generally require
a 20e30% larger sample size than a NI design.2.6. Possible outcomes of hypothetical study results: illustration of
an equivalence design (RBP vs. SBP)
To understand some of the differences in data interpretation that
can arise when deciding to conduct a comparability trial based on an
EQ design vs. a NI design, Fig. 4 schematically illustrates a range of
possible outcomes of an EQ study of the type we have been dis-
cussing and how each might be interpreted relative to the primary
objective of the study, i.e. can the efﬁcacy of the newly developed
SBP be declared clinically similar to the reference product with
which it has been compared, based on the pre-speciﬁed statistical
and clinical criteria? Similarly Fig. 5 provides the same range of
outcomes, but somewhat different interpretations of the data are
required if the study uses a NI design. Each ﬁgure presents possible
outcomes (Scenarios A through F) in the form of a point estimate
(and 95% conﬁdence interval(s) around that estimate) for the efﬁcacy
treatment differences between the SBP and the RBP.
The light blue tinted area in Fig. 4 represents the pre-speciﬁed
zone of equivalence (7% worse to 7% better than) when compared
to the RBP. For scenario A, where both the point estimate and 95% CI
of the difference between SBP and RBP falls outside of the zone of
equivalence, the SBP is not equivalent to the RBP. For scenarios B
through D, however, the point estimate and CI’s do completely fall
within the blue equivalence zone, so for all of these outcomes the
SBP would be declared equivalent to (“just as good as”) the RBP.
This is the case even though in scenario B the SBP is statistically
worse than the RBP and in scenario D it is statistically superior to
the RBP. This is because (based on pre-speciﬁed criteria) any
difference in efﬁcacy between the SBP and RBP that is less than 7%
is not felt to be clinically meaningful.
If we now look, for comparison, at these same scenarios, but
based on a NI design (Fig. 5), the light blue tinted area is half
the size as it was in the EQ design, and now represents the
pre-speciﬁed zone of “non-inferiority” (i.e. up to 7% worse) when
Fig. 4. Possible Outcomes of Hypothetical Study Results: Illustration of an Equivalence Design (RBP vs. SBP): Sponsor assumes that their SBP is “just as good as” the RBP product for
treatment of the Target Population if the average Parameter Z response to treatment with the SBP is within 7% of the response to the RBP. Graphic design After: G. Piaggio et al.
JAMA06_295_1152.
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point estimate and 95% CI of the difference between SBP and RBP
falling outside of the zone of non-inferiority, so in this design,
with a Scenario A outcome, the SBP has not been demonstrated
to be non-inferior to the RBP, and the pre-speciﬁed endpoint
would not have been achieved. For scenario B, the point estimate
and CI does completely fall within the blue non-inferiority zone,
so the SBP would be declared non-inferior to (“just as good as”)
the RBP.
When looking at Scenarios CeF in the NI design, the interpre-
tation becomes more complex/problematic. While all of these
scenarios demonstrate the SBP to be clearly “non-inferior” to the
RBP (because the point estimate and CI arewithin or better than the
one-sided non-inferiority margin), Scenario D also demonstrates
that the SBP is statistically superior to the RBP, though it is unclear if
it is clinically superior. In scenario F (the extreme) not only does the
SBP meet the criteria for non-inferiority, it also shows the SBP to beFig. 5. Possible Outcomes of Hypothetical Study Results: Illustration of a Non-inferiority De
for treatment of the Target Population if the average Parameter Z response to treatment wboth statistically and clinically superior to the RBP, with scenario E
being somewhere in-between F and D.
The question then arises for scenarios like D through F as to
whether the SBP should be approved as “similar” to the RBP when
the data suggests the SBP may well be superior. To answer this,
a decision would have to be made about how much “extra efﬁcacy”
would cause any concern about the SBP not being adequately
similar to the RBP and, in particular, might consequently result in
a worse safety proﬁle. So the upper limit of acceptability will either
have to be speciﬁed before the trial is carried out, or after it has
been analyzed. For the beneﬁt of proper planning and objectivity of
choice of margin, it seems better to specify it when the trial is
planned (i.e. before it is carried out).sign (RBP vs. SBP): Sponsor assumes that their SBP is “just as good as” the RBP product
ith the SBP is no more than 7% worse than the response to the RBP.
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As part of the exercise to illustrate the complexity of study
designs and how they can affect the interpretation of trial results,
the participants were asked a number of questions that directed
them to discuss and contrast the data interpretation of a pivotal
clinical trial comparing the target SBP and the RBP, based on an EQ
vs. on a NI design, assuming in one case the results were consistent
with scenario B (the SBP was worse than RBP by 4%) vs. in another
case results were consistent with scenario E (the SBP was better
than RBP by 9%). They were also asked to discuss how these various
outcomes would impact the issue of extrapolation of indications,
i.e. approving additional indications for use of the SBP beyond those
actually studied in the pivotal trial, based solely upon establish-
ment of similarity of the SBP to the RBP in the studied target
population.
The discussion helped to highlight some of the key principles
outlined in the WHO guidance.
Key points brought out included:3.1. For scenario E (the SBP was better than RBP by 9%)
 In the context of an equivalence design, the clinical results from
Scenario E clearly demonstrate that the SBP is not equivalent to
the RBP and therefore would not meet the criteria of
substantial similarity that is required to be considered for
approval through the SBP pathway described in the WHO
guidance. Further, any consideration for extrapolation of indi-
cations would not be relevant, where different efﬁcacy and
safety proﬁles of other patient populations could be impacted
by treatment with a drug that may have a stronger pharma-
cological effect;
 In the context of a non-inferiority design, while the clinical
results from Scenario E demonstrate that the SBP is non-
inferior to the RBP, the data strongly suggest that the SBP is
actually superior to the RBP. However, post-hoc justiﬁcation
that a ﬁnding of statistically superior efﬁcacy for the SBP is not
clinically relevant is difﬁcult for a number of reasons. Impor-
tant examples in this context include:
B While the SBP did show non-inferiority, the statistically and
clinically superior efﬁcacy would limit the SBP’s ability to be
considered for extrapolation of indications;
B The potential for additional safety issues if the SBP has
a higher PD effect at the same dose as the RBP. If such effects
would be considered clinically relevant, then the SBP cannot
be considered similar to the RBP and should be developed as
a stand-alone product, which would require substantially
more clinical data to adequately characterize and conﬁrm its
efﬁcacy, safety and risk-beneﬁt for the target patient
population.3.2. For scenario B (the SBP was worse than RBP by 4%)
 In the context of an equivalence design, the clinical results from
Scenario B demonstrate that the SBP is equivalent to the RBP
and therefore would meet the criteria of substantial similarity;
even though the SBP was statistically inferior to the RBP (see
section 2.4.4 and Fig. 4).
 In the context of the non-inferiority design the conclusions
would be similar, i.e. that the SBP was non-inferior to the RBP;
and again would meet the criteria of substantial similarity.3.3. For the issue of extrapolation of indications
In most cases, demonstration of equivalence or non-inferiority
of the SBP in a given indication should not routinely allow
extrapolation to other indications for which the RBP has been
approved without additional clinical data. In some limited cases,
extrapolation may be reasonable. TheWHO guidance indicates that
“extrapolation of these data to other indications of the RBP (not
studied in independent clinical studies with the SBP) may be
possible if all of the following conditions are fulﬁlled:
A sensitive clinical test model has been used that is able to
detect potential differences between the SBP and the RBP;
 The clinically relevant mechanism of action and/or involved
receptor(s) are the same; e.g. GH action in different conditions
of short stature in children; erythropoiesis-stimulating action
of epoetins in different conditions associated with anemia or
for the purpose of autologous blood donation. If the mecha-
nism of action is different or not known a strong scientiﬁc
rationale and additional data (e.g. “PD ﬁngerprint”, additional
clinical data) will be needed;
 Safety and immunogenicity of the SBP have been sufﬁciently
characterized and there are no unique/additional safety issues
expected for the extrapolated indication(s), for which clinical
data on the SBP is not being provided; e.g. immunogenicity
data in immunosuppressed patients would not allow extrap-
olation to an indication in healthy subjects or patients with
autoimmune diseases while the reverse would be valid;
 If the efﬁcacy trial used a non-inferiority study design and
demonstrated acceptable safety and efﬁcacy of the SBP
compared to the RBP, the applicant should provide convincing
arguments that this ﬁnding can be applied to the extrapolated
indications; e.g. results from a non-inferiority trial in an indi-
cation where a low dose is used may be difﬁcult to extrapolate
to an indicationwhere a higher dose is used, from both efﬁcacy
and safety point of view.”4. Conclusions
This case study exercise of a hypothetical SBP being developed
for a chronic indication provided an opportunity to discuss and
highlight some of the key principles and issues described in the
recently released Guidelines on Evaluation of Similar Bio-
therapeutic Products (SBPs) [2]. Key elements of the guideline that
were discussed included: ensuring the choice of sensitive markers/
endpoints of safety and efﬁcacy, understanding that any clinical
exercise to show similar efﬁcacy and safety is a stepwise procedure,
and appreciating that the keys to a successful comparative clinical
trial include choosing an efﬁcacy endpoint based on a strong
understanding of its effect size, robustness and clinically mean-
ingful equivalence margin. While the use of an equivalence design
is preferred over non-inferiority, the use of either must be justiﬁed
on a case-by-case basis.
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